Elbahnsi A, Dudas B, Callebaut I, Hinzpeter A, Miteva M
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770445
PMC: 11676857.
DOI: 10.3390/ph17121602.
Moralev A, Salomatina O, Salakhutdinov N, Zenkova M, Markov A
Molecules. 2024; 29(20).
PMID: 39459307
PMC: 11510211.
DOI: 10.3390/molecules29204939.
Chang Y, Wu I, Sheu M, Lan Y, Hung C
Int J Mol Sci. 2024; 25(15).
PMID: 39126039
PMC: 11312483.
DOI: 10.3390/ijms25158471.
Fuchs D, Serio L, Balaji S, Sprenger K
Comput Struct Biotechnol J. 2024; 23:2669-2679.
PMID: 39027651
PMC: 11254953.
DOI: 10.1016/j.csbj.2024.06.025.
Elbahnsi A, Dudas B, Cisternino S, Decleves X, Miteva M
Comput Struct Biotechnol J. 2024; 23():2548-2564.
PMID: 38989058
PMC: 11233806.
DOI: 10.1016/j.csbj.2024.06.010.
Membrane-Fusing Vehicles for Re-Sensitizing Transporter-Mediated Multiple-Drug Resistance in Cancer.
Vahdati S, Lamprecht A
Pharmaceutics. 2024; 16(4).
PMID: 38675154
PMC: 11053612.
DOI: 10.3390/pharmaceutics16040493.
Regulation of P-Glycoprotein during Oxidative Stress.
Shchulkin A, Abalenikhina Y, Kosmachevskaya O, Topunov A, Yakusheva E
Antioxidants (Basel). 2024; 13(2).
PMID: 38397813
PMC: 10885963.
DOI: 10.3390/antiox13020215.
Consensus screening for a challenging target: the quest for P-glycoprotein inhibitors.
Governa P, Biagi M, Manetti F, Forli S
RSC Med Chem. 2024; 15(2):720-732.
PMID: 38389870
PMC: 10880898.
DOI: 10.1039/d3md00649b.
Study Models of Drug-Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels.
Veiga-Matos J, Morales A, Prieto M, Remiao F, Silva R
Molecules. 2023; 28(22).
PMID: 38005253
PMC: 10673607.
DOI: 10.3390/molecules28227532.
Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1.
Shchulkin A, Erokhina P, Goncharenko A, Mylnikov P, Chernykh I, Abalenikhina Y
Pharmaceuticals (Basel). 2023; 16(11).
PMID: 38004395
PMC: 10674565.
DOI: 10.3390/ph16111529.
Bioinformatic analysis of highly consumed phytochemicals as P-gp binders to overcome drug-resistance.
Rajaei N, Rahgouy G, Panahi N, Razzaghi-Asl N
Res Pharm Sci. 2023; 18(5):505-516.
PMID: 37842517
PMC: 10568960.
DOI: 10.4103/1735-5362.383706.
Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory site.
Phondeth L, Kamaraj R, Nilles J, Weiss J, Haefeli W, Pavek P
Arch Toxicol. 2023; 98(1):223-231.
PMID: 37833491
PMC: 10761502.
DOI: 10.1007/s00204-023-03618-w.
Fighting Multidrug Resistance with Ruthenium-Cyclopentadienyl Compounds: Unveiling the Mechanism of P-gp Inhibition.
Teixeira R, Salaroglio I, Oliveira N, Sequeira J, Fontrodona X, Romero I
J Med Chem. 2023; 66(20):14080-14094.
PMID: 37616241
PMC: 10614197.
DOI: 10.1021/acs.jmedchem.3c01120.
Pinostrobin and Tectochrysin Conquer Multidrug-Resistant Cancer Cells via Inhibiting P-Glycoprotein ATPase.
Wu I, Kuo C, Su C, Lan Y, Hung C
Pharmaceuticals (Basel). 2023; 16(2).
PMID: 37259354
PMC: 9963356.
DOI: 10.3390/ph16020205.
Ligand- and Structure-based Approaches for Transmembrane Transporter Modeling.
Grandits M, Ecker G
Curr Drug Res Rev. 2023; 16(2):81-93.
PMID: 37157206
PMC: 11340286.
DOI: 10.2174/2589977515666230508123041.
Impact of Plastic-Related Compounds on P-Glycoprotein and Breast Cancer Resistance Protein In Vitro.
Rosellini M, Turunen P, Efferth T
Molecules. 2023; 28(6).
PMID: 36985682
PMC: 10058098.
DOI: 10.3390/molecules28062710.
The Molecular Mechanisms of Oleanane Aldehyde-β-enone Cytotoxicity against Doxorubicin-Resistant Cancer Cells.
Moiseeva N, Eroshenko D, Laletina L, Rybalkina E, Susova O, Karamysheva A
Biology (Basel). 2023; 12(3).
PMID: 36979107
PMC: 10045559.
DOI: 10.3390/biology12030415.
Interaction of a Homologous Series of Amphiphiles with P-glycoprotein in a Membrane Environment-Contributions of Polar and Non-Polar Interactions.
Moreno M, Filipe H, Cunha S, Ramos C, Martins P, Abel B
Pharmaceutics. 2023; 15(1).
PMID: 36678803
PMC: 9862096.
DOI: 10.3390/pharmaceutics15010174.
Analysis of P-Glycoprotein Transport Cycle Reveals a New Way to Identify Efflux Inhibitors.
Grigoreva T, Vorona S, Novikova D, Tribulovich V
ACS Omega. 2022; 7(47):42835-42844.
PMID: 36467933
PMC: 9713869.
DOI: 10.1021/acsomega.2c04768.
The Tetrahydroisoquinoline Scaffold in ABC Transporter Inhibitors that Act as Multidrug Resistance (MDR) Reversers.
Teodori E, Braconi L, Manetti D, Romanelli M, Dei S
Curr Top Med Chem. 2022; 22(31):2535-2569.
PMID: 36284399
DOI: 10.2174/1568026623666221025111528.